Related Experiment Videos
The Relationship Between Tamoxifen, Estrogen, and Depressive Symptoms
Diane S. Thompson1, Cynthia A. Spanier, Victor G. Vogel
1Magee-Womens Hospital, Pittsburgh Cancer Institute, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
The Breast Journal
|May 12, 2001
Summary
Tamoxifen, a breast cancer treatment, may cause depression by affecting mood-regulating neurotransmitters. Monitoring and treating depression is crucial for patients undergoing tamoxifen therapy.
Area of Science:
- Oncology
- Neuroendocrinology
- Psychiatry
Background:
- Tamoxifen is a cornerstone in breast cancer treatment.
- While effective, tamoxifen use is associated with clinically significant depression.
- Depression in breast cancer patients can stem from various factors, including treatment and psychological distress.
Purpose of the Study:
- To review reported cases of depression linked to tamoxifen.
- To explore the specific properties of tamoxifen that may contribute to depressive symptoms.
- To highlight the need for further research into tamoxifen-associated depression.
Main Methods:
- Literature review of studies reporting depression in tamoxifen users.
- Analysis of tamoxifen's potential neuroendocrine mechanisms.
- Consideration of confounding factors in breast cancer patient depression.
Main Results:
- Tamoxifen may induce depression through neuroendocrine pathways.
- Its antagonist activity might block estrogen's neuroprotective effects.
- This blockade could lead to reduced serotonin and norepinephrine levels, impacting mood.
Conclusions:
- Tamoxifen's impact on neurotransmitters warrants attention as a cause of depression.
- Depression can affect immune function and survival in breast cancer patients.
- Careful risk-benefit assessment and monitoring for depressive symptoms are essential for patients on tamoxifen.